Objectives: To describe HbA1c trends 1-year post treatment intensification to insulin or non-insulin agents in patients with insufficient HbA1c control while on 2 oral antidiabetic agents (2 OADs).

Methods: A retrospective cohort study was conducted in a regional health plan claims database from 1/1/2010 to 3/31/2017. Included patients had type 2 diabetes (T2D) and their treatment was intensified with insulin, a GLP-1 receptor agonist (GLP-1RA) or a 3rd OAD within a year from an HbA1c ≥7.0% while on 2 OADs. HbA1c was estimated monthly by intensification with insulin or non-insulin (i.e., GLP-1RA and 3rd OAD) agents using a mixed-effect model.

Results: The study analyzed a total of 3,909 HbA1c measures from 1,226 patients. HbA1c reductions were significant, but most patients continued to have inadequate glycemic control (HbA1c ≥7.0%). Those receiving insulin had a higher baseline HbA1c (p<0.01), but showed more substantial HbA1c decrease vs. those intensified with a non-insulin agent (p<0.01), controlling for baseline HbA1c.

Conclusion: In patients with T2D, intensification following suboptimal glycemic control while on 2 OADs was associated with significant improvement in HbA1c control. Insulin intensification was associated with worse control at baseline, but greater HbA1c reduction than non-insulin intensification. Additional opportunity exists to improve glycemic control.

K. Kim: None. S. Unni: Research Support; Self; AstraZeneca, Sanofi-Aventis. D. Brixner: Research Support; Self; Sanofi. S. Thomas: Employee; Self; Sanofi. Stock/Shareholder; Self; Sanofi. C.J. Olsen: None. K.L. Sterling: Employee; Self; Sanofi. Stock/Shareholder; Self; Eli Lilly and Company. M. Mitchell: None. C. McAdam-Marx: Research Support; Self; AstraZeneca, Sanofi.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.